{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:53:38Z","timestamp":1792673618213,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12032-018-1080-0","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T08:39:11Z","timestamp":1517387951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma"],"prefix":"10.1007","volume":"35","author":[{"given":"Anton","family":"Uryvaev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Passhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Hershkovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6579-1841","authenticated-orcid":false,"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","volume":"29","author":"DG DeNardo","year":"2010","unstructured":"DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010;29:309\u201316. \n                    https:\/\/doi.org\/10.1007\/s10555-010-9223-6\n                    \n                  .","journal-title":"Cancer Metastasis Rev"},{"key":"1080_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93\u2013103. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.189\n                    \n                  .","journal-title":"Br J Cancer"},{"key":"1080_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1078-0432.CCR-1161-03","volume":"10","author":"A Lad\u00e1nyi","year":"2004","unstructured":"Lad\u00e1nyi A, Somlai B, Gilde K, Fej\u00f6s Z, Gaudi I, T\u00edm\u00e1r J. T-Cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521\u201330.","journal-title":"Clin Cancer Res"},{"key":"1080_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1309\/AJCPTXMEFOVYWDA6","volume":"133","author":"UN Rao","year":"2010","unstructured":"Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010;133:646\u201353. \n                    https:\/\/doi.org\/10.1309\/AJCPTXMEFOVYWDA6\n                    \n                  .","journal-title":"Am J Clin Pathol"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","volume":"14","author":"KI Al-Shibli","year":"2008","unstructured":"Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14:5220\u20137. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0133\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"1080_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cncr.23712","volume":"113","author":"O Kawai","year":"2008","unstructured":"Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer. 2008;113:1387\u201395. \n                    https:\/\/doi.org\/10.1002\/cncr.23712\n                    \n                  .","journal-title":"Cancer"},{"key":"1080_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","volume":"94","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275\u201380.","journal-title":"Br J Cancer"},{"key":"1080_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju435","author":"KA Schalper","year":"2015","unstructured":"Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015. \n                    https:\/\/doi.org\/10.1093\/jnci\/dju435\n                    \n                  .","journal-title":"J Natl Cancer Inst."},{"key":"1080_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF Mutation. N Engl J Med. 2015;372:320\u201330. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412082\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1080_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504030\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1080_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504627\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1080_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki S, Garrig\u00f3s C, Duran I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116\u201324. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.001\n                    \n                  .","journal-title":"Crit Rev Oncol Hematol"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010). Lancet. 2016;387:1540\u201350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7\n                    \n                  .","journal-title":"Lancet"},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.jtho.2016.08.110","volume":"11","author":"R Hui","year":"2016","unstructured":"Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol. 2016;11:S241\u20132. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2016.08.110\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1080_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"issue":"2 Pt A","key":"1080_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.molimm.2015.02.009","volume":"67","author":"A Swaika","year":"2015","unstructured":"Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 andanti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67(2 Pt A):4\u201317. \n                    https:\/\/doi.org\/10.1016\/j.molimm.2015.02.009\n                    \n                  .","journal-title":"Mol Immunol"},{"key":"1080_CR18","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"1080_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371. \n                    https:\/\/doi.org\/10.1038\/nature13954\n                    \n                  .","journal-title":"Nature"},{"key":"1080_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2\n                    \n                  .","journal-title":"Lancet Oncol."},{"key":"1080_CR21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1503093\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1080_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1501824\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1080_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4:674\u201387. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0458\n                    \n                  .","journal-title":"Cancer Discov"},{"key":"1080_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7497\/j.issn.2095-3941.2015.0022","volume":"12","author":"M Santarpia","year":"2015","unstructured":"Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med. 2015;12:74\u20138. \n                    https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0022\n                    \n                  .","journal-title":"Cancer Biol Med."},{"key":"1080_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868\u201376. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.001\n                    \n                  .","journal-title":"Cancer Treat Rev"},{"key":"1080_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","volume":"21","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21:462\u201373. \n                    https:\/\/doi.org\/10.1007\/s10147-016-0959-z\n                    \n                  .","journal-title":"Int J Clin Oncol."},{"key":"1080_CR27","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3006504\n                    \n                  .","journal-title":"Sci Transl Med."},{"key":"1080_CR28","unstructured":"Zakharia Y, Drabick JJ, Khleif S, McWilliams RR, et al. Updates on phase 1b\/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. J Clin Oncol. 2016;34:suppl; abstr 3075. Status\u2014Recruiting, Phase of Trial: Phase I\/II Latest Information Update: 07 Sep 2017."},{"key":"1080_CR29","doi-asserted-by":"publisher","first-page":"e86014","DOI":"10.1172\/jci.insight.86014","volume":"1","author":"RS Dronca","year":"2016","unstructured":"Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016;1:e86014. \n                    https:\/\/doi.org\/10.1172\/jci.insight.86014\n                    \n                  .","journal-title":"JCI Insight"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1080-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T04:03:27Z","timestamp":1548907407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1080-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1080-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"27 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"25"}}